Breast cancer (BC) is the most common cancer in women worldwide. One in eight women will develop the disease in her lifetime. Notwithstanding the incredible progress made in this field, BC still represents the second most common cause of cancer-related death in women. Targeted drugs have revolutionised breast cancer treatment and improved the prognosis as well as the life expectancy of millions of women. However, the phenomenon of primary and secondary pharmacological resistance is becoming increasingly evident, limiting the efficacy of these agents and calling for a better in-depth knowledge and understanding of the biology as well as the biochemical crosstalk underlying the disease. The advent of laboratory technologies in the clinical setting such as the routine use of next generation sequencing has allowed identification of new genetic alterations as well as providing a precise picture of the molecular landscapes of each tumour. Consequently, new specific therapeutic approaches are becoming available to minimise or delay the occurrence of resistance. In this review, we analyse the latest research and news from the clinical development side for each BC subtype.

Advances in systemic therapy for metastatic breast cancer: future perspectives / Corona, S. P.; SOBHANI, NAVID; IANZA, ANNA; ROVIELLO, GIANDOMENICO; MUSTACCHI, GIORGIO; BORTUL, MARINA; ZANCONATI, FABRIZIO; GENERALI, DANIELE. - In: MEDICAL ONCOLOGY. - ISSN 1357-0560. - ELETTRONICO. - 34:(2017), pp. "-"-"-". [10.1007/s12032-017-0975-5]

Advances in systemic therapy for metastatic breast cancer: future perspectives

ROVIELLO, GIANDOMENICO;
2017

Abstract

Breast cancer (BC) is the most common cancer in women worldwide. One in eight women will develop the disease in her lifetime. Notwithstanding the incredible progress made in this field, BC still represents the second most common cause of cancer-related death in women. Targeted drugs have revolutionised breast cancer treatment and improved the prognosis as well as the life expectancy of millions of women. However, the phenomenon of primary and secondary pharmacological resistance is becoming increasingly evident, limiting the efficacy of these agents and calling for a better in-depth knowledge and understanding of the biology as well as the biochemical crosstalk underlying the disease. The advent of laboratory technologies in the clinical setting such as the routine use of next generation sequencing has allowed identification of new genetic alterations as well as providing a precise picture of the molecular landscapes of each tumour. Consequently, new specific therapeutic approaches are becoming available to minimise or delay the occurrence of resistance. In this review, we analyse the latest research and news from the clinical development side for each BC subtype.
2017
34
"-"
"-"
Corona, S. P.; SOBHANI, NAVID; IANZA, ANNA; ROVIELLO, GIANDOMENICO; MUSTACCHI, GIORGIO; BORTUL, MARINA; ZANCONATI, FABRIZIO; GENERALI, DANIELE...espandi
File in questo prodotto:
File Dimensione Formato  
10.1007-s12032-017-0975-5.pdf

Accesso chiuso

Dimensione 981.9 kB
Formato Adobe PDF
981.9 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1156795
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 36
social impact